Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia

Similar documents
Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Summary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017

9/26/2014. Epidemiology of chronic hepatitis B in key priority populations. Declaration of Interest. Advisory. Prevalence - similarities

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis

Policy Document. Vaccination Policy. Background

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Hepatitis B and Hepatitis B Vaccine

EAST LONDON INTEGRATED CARE

HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium

Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific

Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand

REVIEW PRIORITIES AND CHALLENGES FOR HEPATITIS B CONTROL IN THE PHILIPPINES AND THE IMPORTANCE OF A VACCINE DOSE AT BIRTH

NHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

HBV in New Zealand Community HBV screening to long-term follow-up

EPIDEMIOLOGY OF VACCINE-PREVENTABLE VIRAL INFECTIONS IN ABORIGINAL & TORRES STRAIT ISLANDER AUSTRALIANS

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

NHS public health functions agreement

Hepatitis B and Measles Immunity Seroprevalence Survey (HBMISS) Technical Report

VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE 7. 7

The Global Burden of Viral Hepatitis

HEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011

Perinatal Hepatitis b Prevention

HEPATITIS B: Edina Amponsah-Dacosta. Post-Vaccination Surveillance JEFFREY MPHAHLELE. On behalf of. Head

VIRUS HEPATITIS IN PREGNANCY. Yvonne Cossart. Viruses in May- 2009

Hepatitis B (Hep-B) is one of the most

Update of Childhood Vaccination on the Gold Coast

2018 Perinatal Hepatitis B Summit. Eva Hansson, RN, MSN Perinatal Hepatitis B Prevention Coordinator

Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida

Viral Hepatitis in Reproductive Health

Under-immunisation in migrant communities: the measles outbreak in southwestern

Yakima Health District BULLETIN

universal vaccination

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

EVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN)

Call to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China

National AIDS Registry

PERINATAL HEPATITIS B

Hepatitis and pregnancy

Global Epidemiology and Prevention of Hepatitis B

Hepatitis B and C in Australia. Annual Surveillance Report Supplement 2016

Trends in hepatocellular carcinoma, Victoria, Australia,

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Update on Hepatitis B and Hepatitis C

Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes

Quote. These are my principles. If you don t like them I have others. Groucho Marx

Viral Hepatitis Burden and Policy Directions in the European Region of WHO

Prevention of liver cancer and care of people living with Chronic Hepatitis B. Presenters Dr. Nicole Allard and Vanessa Towell.

Hepatitis B at a Glance

PHN - Western Victoria Immunisation Forum Chelsea Taylor Senior Policy Advisor Immunisation, DHHS 21 October 2017

Primary and secondary hepatitis prevention and control programmes The Netherlands

No Jab, No Pay New Immunisation Requirements for Family Assistance Payments

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

Hepatitis B Vaccination-A Singapore. Citation Acta medica Nagasakiensia. 1986, 30

Surveillance and epidemiology of blood borne viral hepatitis in Australia: 21 years of the National Notifiable Disease Surveillance System

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

STATE TDAP VACCINE PROGRAM

What do we need to better understand the needs of mobile and migrant populations in Australia? Is a HIV national response achievable?

Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Annual Surveillance Report

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Hepatitis B vaccination worldwide: Lessons learnt and the way forward

California Immunization Coalition 2018 Summit Karen Smith, MD, MPH, Director California Department of Public Health

Progress in maternal and child health: Uzbekistan and WHO European Region

Maternal influenza immunisation

HBV in the UK: economic aspects

Influenza Surveillance to Inform Decision Making

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Acknowledgment. Natural history of hepatitis B virus (HBV) infection. Background on hepatitis B

Hepatitis Serology and Background Notes

Burden of disease & the Australian Rheumatic Fever Strategy

Monitoring vaccine-preventable diseases is

Hepatitis B virus (HBV) infection is an important. Brief Communication

Immunisation coverage How much do we need? How do we get there?

Obstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School

OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program

MENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018

Chapter 5 Serology Testing

Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program

Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people. Annual Surveillance Report 2017

Reducing differences in the uptake of immunisation (PH21): Frequently asked questions for staff in Sure Start Children s Centres

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

Chapter 2 Hepatitis B Overview

Emerging infectious threats in Indigenous populations

SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat

ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design

Monitoring hepatitis C treatment uptake in Australia

Perinatal Hepatitis B Prevention Program. Purpose

ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university

Management of Hepatitis B - Information for primary care providers

Hepatitis B Positive: Care of Mother Policy

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

Aboriginal and Torres Strait Islander women and cervical cancer prevention. Menzies School of Health

Transcription:

Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia Tilman Ruff Nossal Institute for Global Health, University of Melbourne Consultant: Australian Red Cross, WHO Immunisation policy for migrants, refugees and travellers UNSW 9 Aug 2013

Acknowledgements Ben Cowie, Jennifer MacLachlan, WHO Regional Reference Laboratory for Hepatitis B, VIDRL Karen Hennessey, WHO Ian Gust

Hepatitis B : essential facts 360 million carriers globally The most contagious blood-borne virus Chronic carriage risk highest early in life; acute disease more likely in adolescence/adulthood Chronic HB can cause chronic hepatitis, cirrhosis and primary hepatocellular carcinoma 15-25% risk premature mortality for early infection Accounts for up to 80% of liver cancer Second only to tobacco as fatal carcinogen Eventually eradicable

HB is different from other vaccine-preventable diseases Most infections asymptomatic / unrecognised until a complication develops Complications usually develop after decades Causative role of HB may not be recognised Preventing HB is not so much a child survival issue but primarily an issue of premature adult death The first vaccine against cancer The only infant vaccine where timing of first dose is critical

HB burden of disease in Western Pacific Region 28% global population 45% carriers - 160 million 325,000 deaths / yr: 890 / day ~= TB In absence of immunisation, 2.2% of annual birth cohort of WPR would be expected to die of HBrelated causes HB currently causes more deaths than any other disease targeted by universal immunisation except pneumococcal disease WPRO. Progress in HB control in WPR. Manila 2004 Goldstein S et al. Int J Epidemiol 2005;34:1329-39

Risk of chronic infection 100 80 % Risk 60 40 20 0 Neonates Infants Children Adults Age at Infection

HB Australia immunisation milestones 1982 HB vaccine available (plasma-derived) The most expensive vaccine at that time 1983 - NHMRC guidelines targeted to high risk groups (including infants of carrier mothers) 1984 - Universal infant immunisation proposal by Director, Communicable Diseases Section, DOH 1987 - Federal funding for immunisation of infants born in high risk ethnic groups Recombinant vaccine available

HB immunisation milestones 2 1987 Nov at-risk infants NT Jan 88, SA 1996 1990 NT universal infant 1996 NHMRC rec universal infant + adolescent programs 1998 Jan adolescents Qu, Tas, NT Mar-Apr 98; NSW, SA 1999 School programs key variable timing Pre 98 ACT, SA, Tas, Vic; after 2002 Q, NSW, WA 2000 May universal infant including dose at birth

Prevention of mother to infant transmission Immunisation of infants born to carrier mothers Victoria 1991-2, n=336 Of those recorded in local government records HB3 coverage 80.8% Of entire cohort documented HB3 coverage 57.4% Oman KM et al. Aust NZ J Public Health 1997; 21:731-4

Prevention of mother to infant transmission Immunisation of infant born to carrier mothers NSW 1987-8 Inner Sydney 41/49 (81%) coverage HB3 NSW Reznik R. Med J Aust 1991; 155:153-6 SE Sydney, 13/20 (65%) infants of Chinese carrier mothers received HBIG, HB3 100% Su J et N. Med J Aust 1997; 166:446-7

Prevention of mother to infant transmission Immunisation of infants born to carrier mothers SW Sydney, 1997 After period of follow-up using ACIR data, completed coverage increased from 22 to 46% Crone S, et al. 6th Nat Imm Conf, Melb 4-5.11.98 50% of NSW areas reporting, 1-3/99 38/39 babies identified HBIG < 12 hr 34/39 HB3 < 6 mo personal communication

Prevention of mother to infant transmission Maternal HB Screening NSW, 1990, Medicare data,+> 10,000 77% pregnant women screened Rushworth RL et al. Aust J Public Health 1994; 18:401-6

High risk ethnic groups Victoria 1992-3, n = 3611 Documented HB3 64% DTP/CDT3 > 84% (p < 0.001) Oman K M et al. Aust NZ J Public Health 1997; 21:293-6 Victoria 1997, n = 500, mo country of birth or Aboriginality HB vaccination in hospital 6% Complete HB immunisation by 12m for infants registered with local council programs : 38% Beckmann K, Lester R. 6th Nat Imm Conf, Melb 4-5.11.98

High risk ethnic groups NSW (SW), 1987-90, n = 323 Carrier mother or high risk ethnic group, 69% Aboriginal HB3 60% Riley R et n. Aust J PH 1993; 17:171-3

Universal infant HB immunisation Australia Introduced in NT in 1990 Introduced nationally with a routine dose at birth within 24 hours in 2000 Low program costs Initial education and engagement of hospital staff not normally involved in infant immunisation required for implementation Routine combine with oxytocin for mother and Vitamin K for baby in delivery room

Efficacy of a vaccination programme: Taiwan Incidence of HCC in children 6-14 years old (per 100,000) 8 7 6 5 4 3 2 1 0 7.1 4.5 2.4 1.7 1981 1991 1992 1993 Chen D et al. Hepatitis B vaccines: status report on long-term efficacy. ISVH&LD. 1996. Abstract 147

HBsAg rate, school children born 1985 96: Malaysia 190,077 school children aged 7-12 yrs (1985-1996) Cross-sectional seroprevalence study % 5 4 3 2 1 0 2.5 Start of HBV immunisation 1985 1986 1987 1988 1989 1990 Year of Birth 1991 1992 1993 1994 1995 1996 0.4 HBsAg Carrier Rate (%) Ref: KP Ng et al. Med Micro and Immu (online 19 Oct 2004) Accessed at www.springerlink.com

HBsAg in primary school children - Singapore % 6 5 4 3 2 HBsAg positive 1 0 0% 1972 1987 1994 Babies of carrier mothers All newborns James L. Singapore Med J. 2001 Sep;42(9):420-4

Incidence of acute HB Singapore 1985-2002 10 9 8 7 6 5 4 3 2 1 0 1985 Babies of carrier mothers 1987 All newborns 1996 2002 Reported acute indigenous HB cases (per 100,000) No indigenous cases reported in < 15 y olds since 1997 Goh KT.Ann Acad Med Singapore. 1997 Sep;26(5):671-81. MoH The Childhood Immunization Programme in Singapore, Health Report 2003; www.moh.gov.sg